Anika Appoints Michael Levitz as Chief Financial Officer
August 05 2020 - 4:09PM
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint
preservation, restoration and regenerative solutions company with
products across the orthopedic early intervention continuum of
care, today announced the appointment of Michael Levitz as
Executive Vice President, Chief Financial Officer and Treasurer,
starting August 10, 2020. Mr. Levitz brings over 20 years of public
company financial experience to Anika and has helped deliver
significant increases in enterprise value and operating performance
at several medical device companies. He succeeds Sylvia Cheung, who
will continue with the Company in an advisory capacity for a period
following the succession effective date to assist with a smooth
transition.
“Anika is delighted to welcome Mike to our leadership team
during this pivotal time of momentum and growth for the Company,”
said Cheryl R. Blanchard, Ph.D., President and Chief Executive
Officer of Anika. “His extensive experience building, developing,
and retaining high-performing teams during significant periods of
growth and transformation will be invaluable as we continue to
integrate the acquisitions of Parcus Medical and Arthrosurface,
leverage our expanded global commercial reach, and advance our
strategic growth plan.”
“Anika is at an exciting stage of its corporate evolution, with
a strong financial foundation and a robust and growing early
intervention orthopedic product portfolio and pipeline,” said Mr.
Levitz. “I look forward to contributing to the Company’s culture of
financial discipline and investment in innovation to accelerate
growth and value creation for shareholders.”
Prior to joining Anika, Mr. Levitz served as Senior Vice
President, Chief Financial Officer and Treasurer of Insulet
Corporation, a global innovative medical device and drug delivery
company. Prior to Insulet, from 2009 to 2015 he was the Senior Vice
President, Chief Financial Officer and Treasurer of Analogic
Corporation, a global provider of medical guidance, diagnostic
imaging and threat detection equipment. Previously, during his
seven years with Hologic, Inc. and Cytyc Corporation (which merged
with Hologic in October 2007), Mr. Levitz served in various
capacities including Vice President and Corporate Controller. Mr.
Levitz began his career in the high technology audit practice at
Arthur Andersen. Mr. Levitz earned his Bachelor of Arts in Business
Economics, with emphasis in Accounting, from the University of
California Santa Barbara and is a certified public accountant. In
2011, he was a finalist for the Boston Business Journal's Chief
Financial Officer of the Year award.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global,
integrated joint preservation, restoration and regenerative
solutions company based in Bedford, Massachusetts. Anika is
committed to delivering products along the orthopedic early
intervention continuum of care to improve the lives of patients,
with a focus on osteoarthritis pain management, sports medicine and
joint preservation, restoration and regeneration. The Company has
close to three decades of global expertise commercializing
innovative products across the orthopedic early intervention
continuum of care. For more information about Anika, please visit
www.anikatherapeutics.com.
For Investor Inquiries: Anika Therapeutics, Inc. Kristen Galfetti,
781-457-9000 Executive Director, Investor Relations
investorrelations@anikatherapeutics.com |
For Media Inquiries: W2O Group Rachel Girard, 617-379-6760
rgirard@w2ogroup.com |
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024